Naltrexone

SAN DIEGO — Patients with decompensated alcohol-associated cirrhosis and ascites taking naltrexone had lower risk for all-cause mortality and liver disease complications, including acute kidney injury and spontaneous bacterial peritonitis.

Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta-analysis published in Obesity.

Obesity medications were prescribed to very few Military Health System beneficiaries between October 2017 and September 2022, according to a study published in Obesity.

Black women tend to prefer to see Black obstetric providers during pregnancy due to past experiences of racism and discrimination, according to a presenter at The Pregnancy Meeting.

Current data support naltrexone use as medication for opioid use disorder in pregnancy, with encouraging perinatal outcomes, according to a systematic review published in Obstetrics & Gynecology.

Most adults with obesity were not prescribed an obesity medication from 2015 to 2023, and of those prescribed an agent, 55% had at least one prescription fill, according to study data published in Diabetes, Obesity and Metabolism.

More than 80% of adults who are prescribed an obesity medication discontinue taking them at 1 year, though persistence rates are higher for adults receiving semaglutide and liraglutide, according to study data.

BOSTON — Oral naltrexone 50 mg safely improved alcohol use-related parameters and decompensation, and also reduced cravings, over 1 year among patients with alcohol use disorder and compensated cirrhosis, according to a presenter.

Naltrexone was effective in achieving abstinence, reducing lapses and improving craving scores at 3 months in patients with alcohol-related cirrhosis, according to data presented at EASL Congress.

MIAMI BEACH, Fla. — Adults with binge-eating disorder who were given acute naltrexone/bupropion performed better with similar maintenance treatment compared with placebo, per data from the American Society of Clinical Psychopharmacology annual meeting.